Back to news

Candel Therapeutics Investors Should Contact Block & Leviton to Possibly Recover Losses

ACCESSWIRE•16/11/2026•11:10 ET
1

Key Highlights

  • ➤Candel delays aglatimagene FDA application to mid-2027 from fourth-quarter 2026
  • ➤Candel cited assay refinement timelines and ongoing FDA discussions for the delay
  • ➤Candel shares fell about 39% after-hours following the disclosure
  • ➤Candel entered a new $50 million stock sale agreement
  • ➤Block & Leviton is investigating potential securities law violations

BOSTON, MA / ACCESS Newswire / November 16, 2026 / Block & Leviton is investigating Candel Therapeutics (NASDAQ:CADL) for potential securities law violations. Investors who have lost money in their Candel Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/cadl. What is this all about?

Block & Leviton is investigating whether Candel Therapeutics may have misled investors about the readiness of its application for FDA approval of aglatimagene, its lead prostate cancer drug. In the months before the news, the company reportedly said that manufacturing process validation was "progressing well" and that the inputs for its Biologics License Application remained "on track" for submission in the fourth quarter of 2026, while it was also selling stock to the public. On November 12, 2026, alongside its third-quarter results, Candel disclosed that it now plans to submit the application in mid-2027, citing "timelines associated with assay refinement" and ongoing discussions with the FDA. That same evening, the company entered into a new $50 million stock sale agreement, and its shares fell as much as about 39% in after-hours trading. The investigation focuses on what the company knew about the assay issue, and when, compared with what it was telling investors.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in